“TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS” OBTAINS DRUG REGISTRATION APPROVAL
“Tofacitinib Citrate Extended-Release Tablets (11mg)” developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.
Latest Results of Duomeisu in the Treatment of Sarcoma Released
A study about Duomeisu was successfully published in the journal of Clinical Cancer Research (IF: 13.801, JCR Division: Medical Division 1).
EXCLUSIVE LICENSE AGREEMENT FOR BATOCLIMAB (HBM9161)
CSPC entered into an exclusive license agreement with “Shanghai HBM”,pursuant to which CSPC obtained an exclusive license from Shanghai HBM to develop, manufacture and commercialize batoclimab (HBM9161) in Greater China.
“LENALIDOMIDE CAPSULES” OBTAINS DRUG REGISTRATION APPROVAL
“Lenalidomide Capsules (25mg)"developed by CSPC has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.
CSPC Selected as China's Top 10 Innovative BigPharma Companies
On September 16, 2022, Menet held an online launch event for its "Innovation Leads Future-2021 China's Top 100 Innovative Biopharma Companies" list. CSPC was selected as one of China's Top 10 Innovative BigPharma Companies, among the top three.
CSPC Selected as One of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022”
Recently, renowned pharmaceutical media “Healthcare Executive” published the list of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022". CSPC is once again among the first tier of the list.